| Despite the overall good prognosis of papillary thyroid carcinoma?PTC?,PTC with multiple lymph node metastases or even distant metastasis is not a rare clinical event.In recent years,several studies have found that different gene mutations in PTC might be related to the tumor invasiveness and prognosis.However,the clinical significance still remains unclear.Thanks to the development of next-generation sequencing technology,rapid high-throughput multi-gene parallel sequencing are now clinically possible.This study retrospectively analyzed 305 PTC patients who underwent surgical treatment in our hospital between August 2017 and January 2018 with their surgical specimens undergone next-generation gene sequencing.The patients'gene sequencing results and clinicopathological data were collected and the relations between different gene mutations and various clinicopathological features,tumor stage and risk of recurrence were analyzed.Risk factors related to the tumor invasiveness were also studied.Results show that BRAFV600E mutation existed in most?68.85%?PTCs,and was found to be associated with tumors larger than 10 mm and those without coexisting Hashimoto's thyroiditis.However,the mutation was found no significant correlations with gender,age,preoperative serum25-OH VitD levels,tumor multifocality,number of lesions,lymph node metastasis or number of metastatic lymph nodes,TNM stage,or recurrence risk stratification.There was no statistically significant effect of BRAFV600E600E mutation combined with other gene mutations on tumor invasiveness.Males,younger age,larger tumors,and more lesions were independent risk factors for PTC invasiveness,while BRAF mutation was not.Thus it suggests that currently,clinicopathological features are still more important and more reliable in evaluation of PTC invasiveness and prognosis than molecular markers like genes.New molecular markers should be needed to make a combined evaluation for more accurate results. |
PDF Full Text Request